

Eastbourne District General Hospital

Kings Drive Eastbourne East Sussex BN21 2UD

24th April 2024 Tel: 0300 131 4500 Website: www.esht.nhs.uk

FOI REF: 24/266

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

1) How many patients were treated in March 2024 (or latest available month) by the Dermatology department with the following drugs:

•	Abrocitinib (Cibinqo)	0
•	Baricitinib (Olumiant)	0
•	Dupilumab (Dupixent)	50
•	Lebrikizumab (Ebglyss)	0
•	Omalizumab (Xolair)	6
•	Tralokinumab (Adtralza)	5
•	Upadacitinib (Rinvoq)	1

2) How many patients were treated in March 2024 (or latest available month) by the Respiratory Medicine departments with the following drugs:

•	Benralizumab (Fasenra)	0
•	Dupilumab (Dupixent)	0
•	Mepolizumab (Nucala)	0
•	Omalizumab (Xolair)	1
•	Reslizumab (Cinqaero)	0
•	Tezepelumab (Tezspire)	0

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (<u>eshtr.foi@nhs.net</u>), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department esh-tr.foi@nhs.net